Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HXN6005 SAD in Healthy Participants
NCT07449741Phase 1Recruiting
- Sponsor
- Helixon
- Start
- Apr 2026
- Primary completion
- Mar 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in asthma comparing HXN6005 SAD with Placebo SAD (2 arms). Primary endpoint: Number of Participants Experiencing Adverse Events. Started Apr 2026; status: recruiting.
02
Drugs
HXN6005
03
Conditions
asthma
Beyond the preview
Go deeper on NCT07449741.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07449741.